Advanced Pathogen Detection Without Incubation Bias

Traditional microbiology relies heavily on the metabolic growth of microorganisms, a process that inherently introduces timeline bottlenecks and selective diagnostic biases. Slow-growing, fastidious, or unculturable organisms are frequently masked on traditional media by dominant, rapidly proliferating flora. Furthermore, when patients have already received empirical antimicrobial therapy prior to sample collection, the clinical sensitivity of standard blood cultures drops precipitously.

The Cube Dx platform bypasses these culturing constraints by utilizing highly sensitive molecular workflows directly on raw clinical specimens. Driven by pan-bacterial 16S and pan-fungal 28S PCR master-mixes, the platform achieves absolute diagnostic depth without overnight propagation.

Comprehensive Syndromic Coverage & The FungiPlus Array

Microbiology laboratories can deploy specific high-multiplex target panels depending on the clinical presentation and specimen matrix:

• The Sepsis Screen (xB/xC Panels):

Simultaneously screens for 55 bacterial species, 10 bacterial genera, 19 fungal species, and 5 fungal genera right from an initial extraction grid.

• Targeted Mycology Depth (FungiPlus):

A dedicated pan-fungal matrix designed to rapidly differentiate and identify 65 distinct fungal species and genera — including extensive Candida, Aspergillus, and Cryptococcus profiles—in just 2.5 hours.

• Respiratory & Tissue Matrices:

Standardized sample treatment protocols expand testing capabilities to bronchoalveolar lavage (BAL), sputum, saliva, and soft tissues (such as heart valves or joint fluid implants).

Resolving Mixed Infections

Because compact sequencing relies on sequence-specific hybridisation on a cylindrical microarray, the technology delivers an completely unbiased read-out of multi-microbial or complex mixed infections. It eliminates the risk of dominant strains overgrowing more fastidious pathogens, giving microbiologists a clear, transparent mapping of the patient's true infection state.

Validated Clinical Performance

The platform's performance metrics are backed by peer-reviewed, multi-centre clinical evaluations published at major European congresses (ECCMID). Validated on hundreds of clinical cases, the platform demonstrates:

• Clinical Specificity: 98.41%
• Negative Predictive Value (NPV): 96.87%
• Limit of Detection (LOD): 20 CFU/mL (and lower for select key targets)

This high negative predictive value enables molecular microbiologists to confidently rule out bloodstream infections hours ahead of culture results, assisting pharmacy teams with immediate antimicrobial stewardship interventions.